Junia V. Melo

Q: What Schools Are Affiliated With Junia V. Melo

Junia V. Melo is affiliated with the following schools: Imperial College London, Royal Postgraduate Medical School, University of Adelaide

Junia V. Melo's AcademicInfluence.com Rankings

Junia V. Melo

Biology

#11074

World Rank

#14449

Historical Rank

Molecular Biology

#1667

World Rank

#1695

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Junia V. Melo Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Junia V. Melo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The molecular biology of chronic myeloid leukemia. (2000) (1641)
Chronic myeloid leukemia--advances in biology and new approaches to treatment. (2003) (959)
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. (2000) (829)
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. (1996) (780)
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. (1997) (677)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. (2013) (625)
Cancer stem cell definitions and terminology: the devil is in the details (2012) (619)
Chronic myeloid leukaemia as a model of disease evolution in human cancer (2007) (603)
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. (2003) (555)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. (2013) (548)
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. (2002) (535)
The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. (1998) (442)
An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. (1994) (283)
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR (2010) (279)
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (2001) (271)
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. (2002) (270)
Roots of clinical resistance to STI-571 cancer therapy. (2001) (222)
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. (2001) (206)
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. (2005) (199)
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? (2009) (195)
Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications (2008) (194)
Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens. (1987) (180)
Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation. (2004) (172)
Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. (2003) (170)
Natural course and biology of CML (2015) (170)
The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia (1986) (169)
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib (2006) (165)
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. (2007) (161)
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. (1996) (159)
Imatinib-resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprogramming (2010) (158)
Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. (2006) (155)
P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? (1994) (155)
BCR-ABL gene variants. (1997) (154)
The ABL-BCR Fusion Gene Is Expressed in Chronic Myeloid Leukemia (1993) (152)
The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. (2007) (151)
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. (2000) (142)
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. (1996) (139)
Resistance to imatinib mesylate in chronic myeloid leukaemia. (2007) (132)
Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. (2002) (132)
Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis (2007) (128)
A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. (2006) (119)
Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro (2004) (118)
Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. (2001) (116)
Cytogenetic studies on prolymphocytic leukemia. 1. B-cell prolymphocytic leukemia. (1987) (116)
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. (2004) (108)
Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. (2003) (104)
Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells (2008) (104)
Cytogenetic and Molecular Genetic Aspects of Chronic Myeloid Leukaemia (2002) (104)
Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia (2007) (102)
The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia (1986) (102)
Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL–Positive Cells (2009) (102)
Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL – Inhibition of P-glycoprotein function by 17-AAG (2005) (99)
BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry (2006) (94)
Hairy cell leukemia (HCL) variant: an intermediate disease between HCL and B prolymphocytic leukemia. (1984) (92)
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. (2010) (90)
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. (2010) (88)
Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation. (1998) (86)
Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia (2005) (81)
Splenic B cell lymphoma with "villous" lymphocytes in the peripheral blood: a disorder distinct from hairy cell leukemia. (1987) (81)
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. (2002) (80)
Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. (2002) (80)
Chronic myeloid leukemia. (2003) (79)
Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. (2003) (78)
The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia (1986) (77)
The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia (1987) (76)
Chromosome abnormalities at 11q13 in B cell tumours (1988) (75)
Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. (2001) (74)
Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition (2017) (70)
Two new cell lines from B‐prolymphocytic leukaemia: Characterization by morphology, immunological markers, karyotype and Ig gene rearrangement (1986) (70)
BCR-ABL in Chronic Myelogenous Leukemia – How Does It Work? (2008) (68)
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway (2010) (63)
Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells (2005) (62)
Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. (2008) (62)
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. (2010) (61)
Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. (2012) (61)
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells (2009) (61)
Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. (2001) (60)
Analysis of genomic breakpoints in p190 and p210 BCR–ABL indicate distinct mechanisms of formation (2010) (59)
The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. (1993) (59)
Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors (2010) (59)
Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. (2003) (57)
Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1. (2007) (57)
Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. (1994) (57)
BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia. (1995) (55)
Lack of correlation between ABL‐BCR expression and response to interferon‐α in chronic myeloid leukaemia (1996) (53)
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. (2011) (51)
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. (2002) (51)
Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results. (1996) (46)
Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease (2004) (46)
Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene (2001) (45)
Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. (2005) (43)
Mutation in the ATP‐binding site of BCR‐ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571 (2002) (43)
The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement. (1988) (42)
The membrane phenotype of hairy cell leukemia: a study with monoclonal antibodies. (1984) (42)
ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. (2001) (42)
The 14q+ marker in hairy cell leukaemia. A cytogenetic study of 15 cases. (1986) (42)
BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis (2003) (41)
Morphology and immunology of circulating cells in leukaemic phase of follicular lymphoma. (1988) (38)
Overcoming STI 571 resistance with the farnesyl transferase inhibitor SCH 66336 (2002) (38)
Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. (2000) (38)
Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia. (1993) (38)
Do we have to kill the last CML cell? (2011) (37)
The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia (2007) (37)
Mechanisms of resistance to BCR–ABL kinase inhibitors (2011) (36)
Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure? (2011) (34)
Upregulation of the TGFβ signalling pathway by Bcr‐Abl: Implications for haemopoietic cell growth and chronic myeloid leukaemia (2007) (34)
Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells. (2002) (33)
Establishment and characterization of three new malignant lymphoid cell lines (1987) (32)
Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies. (2003) (32)
Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate (2003) (32)
The polycomb group BMI 1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia (2007) (31)
Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy (2010) (31)
Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. (2008) (29)
The leukocyte-common antigen (CD45) complex and B-lymphocyte activation. (1990) (28)
The impact of gene profiling in chronic myeloid leukaemia. (2009) (28)
A kinase-independent role for CDK8 in BCR-ABL1+ leukemia (2019) (27)
Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia (2018) (26)
Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5 (2013) (26)
Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib (2006) (23)
Proteasome proteolytic profile is linked to Bcr-Abl expression. (2009) (22)
Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. (2015) (21)
Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells (2012) (21)
Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia. (1996) (20)
Management of chronic myeloid leukemia: targets for molecular therapy. (2003) (20)
Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients (2013) (20)
Production of P‐glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first‐line chemotherapy in advanced breast cancer (2007) (19)
Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. (2011) (19)
Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1 (2009) (19)
Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia (2014) (19)
Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach. (2010) (18)
CD40 and B-cell receptor signalling induce MAPK family members that can either induce or repress Bcl-6 expression. (2009) (18)
Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines (2007) (18)
Inviting leukemic cells to waltz with the devil (2001) (18)
Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models (2014) (18)
Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. (2005) (18)
Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia. (2007) (17)
Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia (2006) (17)
Biological Markers in Lymphoproliferative Disorders (1985) (17)
Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia (2010) (17)
Controls for reverse transcriptase-polymerase chain reaction amplification of BCR-ABL transcripts. (1994) (16)
A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL (2013) (15)
Primary plasma cell leukaemia: immunological and ultrastructural studies in 6 cases. (2009) (15)
Prolymphocytic leukemia of B cell type: rearranged immunoglobulin (Ig) genes with defective Ig production. (1985) (15)
Chronic lymphocytic leukemia and prolymphocytic leukemia: a clinicopathological reappraisal. (1987) (15)
Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient (2012) (15)
Overproduction of BCR‐ABL induces apoptosis in imatinib mesylate‐resistant cell lines (2005) (14)
Short-term intense Bcr–Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL+ cells (2009) (14)
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide through glutathione-depletion in imatinib-resistant cells (2007) (14)
The susceptibility of Philadelphia chromosome positive cells to FAS‐mediated apoptosis is not linked to the tyrosine kinase activity of BCR‐ABL (1998) (13)
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib (2009) (13)
BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir. (2001) (12)
Markers of differentiated B cell leukaemia: CD22 antibodies and FMC7 react with different molecules. (1987) (12)
Splenectomy in advanced chronic lymphocytic leukaemia. (1987) (12)
SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function (2011) (12)
Lack of imprinting of the ABL gene (1994) (12)
Imatinib: can one outwit chronic myeloid leukemia? (2002) (12)
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells. (2007) (11)
Chronic myeloid leukemia – some topical issues (2007) (11)
Different reactivity of monoclonal antibodies against common acute lymphoblastic leukaemia antigen (CD10). (1987) (11)
BCR‐ABL‐positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions (1996) (11)
The Biology and Pathogenesis of Chronic Myeloid Leukemia (2016) (11)
Do we have to kill the last CML cell? (2011) (11)
Cross‐resistance of imatinib mesylate and 17‐aag in imatinib‐resistant cells that overexpress bcr‐abl (2003) (10)
Reply to ‘What do we mean by sensitivity when we talk about detecting minimal residual disease?’ by Steinbach and Debatin (2009) (10)
Nuclear positioning of the BACH2 gene in BCR‐ABL positive leukemic cells (2007) (10)
Reactivity of the monoclonal antibody RFB1 in chronic B-cell leukaemias. (2009) (10)
BCR‐ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia (2012) (9)
Intracytoplasmic inclusions in B prolymphocytic leukaemia: ultrastructural, cytochemical, and immunological studies. (1985) (9)
Imatinib and ABCG2: who controls whom? (2006) (9)
Ex vivo expansion and characterisation of CD34+ cells derived from chronic myeloid leukaemia bone marrow and peripheral blood, and from normal bone marrowand mobilised peripheral blood (2000) (8)
Restoration of sensitivity to STI 571 in STI 571-resistant chronic myeloid leukemia cells (2001) (8)
Chronic myeloid leukemia: the basis of treatment for tomorrow (2011) (8)
Antigenic expression of B-cell chronic lymphocytic leukemic cell lines. (1992) (8)
The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells (2017) (8)
In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis. (2007) (8)
Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia. (1992) (7)
Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib (2009) (7)
Absence of in vitro or in vivo bystander effects in a thymidine kinase-transduced murine T lymphoma (2000) (7)
BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations. (2006) (6)
Response of STI571-resistant cells to other chemotherapeutic drugs and signal transduction inhibitors. (2000) (6)
Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients (2013) (6)
Modulation of the p 38 MAPK ( mitogen-activated protein kinase ) pathway through Bcr / Abl : implications in the cellular response to AraC (2005) (6)
One Year into the COVID-19 Pandemic (2021) (5)
Chronic Myeloid Leukemia: Biology of Advanced Phase (2007) (5)
Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment. (2006) (5)
Balanced parental contribution to the ABL component of the BCR-ABL gene in chronic myeloid leukemia. (1995) (5)
Expression of the LH2 gene in chronic myeloid leukaemia cells. (1996) (5)
Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells (2013) (5)
Pro-survival role of protein kinase C epsilon in Philadelphia chromosome positive acute leukemia (2016) (5)
Handbook of Chronic Myeloid Leukemia (2014) (4)
A Gene Expression Signature of CD34+Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance (2009) (4)
The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. (2017) (4)
Molecular profiling of CD34+ cells identifies low expression of CD7 with high expression of proteinase 3 or elastase as predictors of longer survival in CML patients (*) (2005) (3)
Detection of resistance to STI571 in patients with BCR-ABL positive acute leukemia and chronic myeloid leukemia blast crisis (2000) (3)
Myeloid Leukemia of Multiple Genes Implicated in the Pathogenesis of Chronic Tyrosine Kinase Activity Regulates the Expression BCR-ABL Updated (2000) (3)
Novel compounds with antiproliferative activity against imatinib-resistant cell lines (2007) (3)
Zoledronate is active against imatinib mesylate-resistant chronic myeloid leukemia cell lines and synergistic/additive when combined with imatinib mesylate. (2003) (3)
Advances in Brief Bcr-Abl Kinase Modulates the Translation Regulators Ribosomal Protein S 6 and 4 EBP 1 in Chronic Myelogenous Leukemia Cells via the Mammalian Target of Rapamycin 1 (2003) (3)
Chronic Myeloid Leukaemia (2015) (2)
The Proteome Analysis of an Imatinib-Resistant Cell Line Identifies Changes in Molecular Chaperones Such as Heat Shock Proteins (Hsp): A Possible New Mechanism of Imatinib Resistance. (2004) (2)
Monitoring Response to Treatment (2014) (2)
Enhanced retroviral gene transfer into CML and normal bone marrow, and CML and mobilized peripheral blood CD34+ cells using the recombinant fibronectin fragment CH‐296 (1999) (2)
Management of Patients with Chronic Myeloid Leukemia (2014) (2)
When is a double Philadelphia not a double Philadelphia (2007) (2)
Wrapping BCR-ABL: it's in the bag. (2010) (2)
B Prolymphocytic Leukemia Cell Lines: Phenotype and Response to B Cell Differentiation Factor (1988) (1)
Molecular Basis of Chronic Myeloid Leukaemia (2003) (1)
How cured are CML patients in complete molecular remission (CMR) after stem cell transplantation or imatinib (2007) (1)
The human leucocyte P30 antigen: properties and assessment of value as a clonal marker. (2008) (1)
Association between the Polycomb Group (PcG) BMI-1 Gene Expression and Outcome in Chronic Myeloid Leukemia (CML) Patients Receiving Allogeneic Stem Cell Transplantation (allo-SCT). (2007) (1)
RUNX1 mutations are rare in chronic phase polycythaemia vera (2011) (1)
Molecular Profiling of CD34+ Cells from Diagnosis in CML Patients Identifies Low Expression of CD7 with High Expression of Proteinase 3 or Elastase as Predictors of Longer Survival. (2005) (1)
Metabolic Profile of Imatinib Resistance in CML Cells. (2004) (1)
Neoplastic kappa and lambda cells in a B-PLL with chromosome translocations of both light chain gene regions. (1984) (1)
Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Bcr-Abl Positive Cells. (2006) (1)
Specific action of FGFR inhibitors against t(4;14) positive myeloma cells (2001) (1)
Myeloid Leukemia Development of Resistance to Imatinib Mesylate in Chronic Bcr-Abl Expression Levels Determine the Rate of Updated (2005) (1)
The Biology and Pathogenesis of Chronic Myeloid Leukaemia (2021) (1)
Gains and amplifications of the ABL-NUP214 region in blast stage of CML (2007) (0)
Subject Index Vol. 119, 2008 (2008) (0)
High-Dose Ionizing Radiation Selective Induction of Leukemia-associated Fusion Genes by Updated (2006) (0)
Bcr-Abl Positive Cells Display Increased Proteasome Activity and Greater Sensitivity to Proteasome Inhibition (2008) (0)
Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells. (2009) (0)
Comparative gene expression profile of p185(Bcr-Abl) versus p210(Bcr-Abl) expressing cells. (2004) (0)
The molecular biology of chronic myeloid leukaemia. (1996) (0)
Synergism between 17-AAG and Imatinib in Imatinib-Resistant CML Cells: Inhibition of P-Glycoprotein by 17-AAG as a New Mechanism of Increasing Imatinib Activity. (2004) (0)
To the Editor. ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia (2001) (0)
Reply to ‘Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia?’ by Chunduri et al (2005) (0)
Novel pathway in BCR-ABL signal transduction involves Akt-independent activation of PLC-gamma/mTOR/P70-S6 kinase (2007) (0)
Mechanisms of Co-Operation of DNMT3A Mutations with JAK2 V617F Through Histone H4 Arginine 3 Provides New Insights in MPN Disease Pathogenesis (2011) (0)
Repetitive washing prevents apoptosis after high-dose TKI pulse-exposure. (2012) (0)
Pathophysiology of Chronic Myeloid Leukemia (2011) (0)
Transcriptional Regulation of the Bach2 B-Cell Differentiation and Apoptotic Factor by the Bcr-Abl Oncoprotein. (2005) (0)
Inactivation of HOXAGenes by Hypermethylation in Myeloid and LymphoidMalignancy is Frequent and Associated with Poor Prognosis (2007) (0)
Leukemia Cells via the Mammalian Target of Rapamycin Ribosomal Protein S 6 and 4 EBP 1 in Chronic Myelogenous Bcr-Abl Kinase Modulates the Translation Regulators (2003) (0)
A decreased Level of Shp1 provides an additive survival advantage to the Ph+ Cells of CML Patients and may account for Resistance to Imatinib Treatment (2008) (0)
ORIGINAL ARTICLE BCR-ABL activity and its response to drugs can be determined in CD34 þ CML stem cells by CrkL phosphorylation status using flow cytometry (2006) (0)
leukemia cells Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid (2013) (0)
Reply to Haas: Are ABL and BCR imprinted? (Leukemia 1995; 9: 740-743). (1995) (0)
The gene expression profile of CML CD34+ cells can predict the duration of chronic phase. (2003) (0)
P-122 Transfusion dependency is associated with inferior outcome in very low- and low-risk IPSS-R patients (2013) (0)
Challenges of Treatment: Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia (2014) (0)
Resistance to imatinib mesylate in CML: all BCR-ABL mutations “are created equal but some are more equal than others” (2003) (0)
OTT-3971-Targeted treatment of imatinib-resistant chronic my (2009) (0)
Multiple molecular mechanism may account for resistance to imatinib in resistant cell lines (2007) (0)
prognosis of chronic myeloid leukemia The polycomb group BMI-1 gene is a molecular marker for predicting (2013) (0)
Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia (2015) (0)
with imatinib response in chronic-phase chronic myeloid leukemia patients treated cells to predict major cytogenetic + A gene expression signature of CD34 (2011) (0)
leukemia cell line models MDR1 gene overexpression confers resistance to imatinib mesylate in (2013) (0)
reduced antigen processing, and impaired migration Dendritic cells from CML patients have altered actin organization, (2013) (0)
Chronic myeloid leukemia: the possibility of a cure (2013) (0)
BCR-ABL-Induced Downregulation of GADD45G in Chronic Myeloid Leukemia (2012) (0)
Activation of the P38 MAPK Pathway Mediates Resistance to Ara-C y Bcr/Abl Positive Cells. (2005) (0)
SCH66336 Overcoming STI571 resistance with the farnesyl transferase inhibitor (2013) (0)
Contents Vol. 119, 2008 (2008) (0)
Short –Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+ Cells Unless They Are Growth Factor Deprived. (2008) (0)
Glutathione-Depletion Potently Enhances the Cytotoxic Activity of Arsenic Trioxide in Imatinib Sensitive and Resistant Bcr-Abl Positive Cell Lines. (2004) (0)
Down-Modulation of Shp1 and Hsp70 Provides a Survival Advantage to the Ph+ Cells of CML Patients Additive to That Related to the Oncogenic BCR/ABL Protein and May Account for Resistance to Ima Treatment. (2007) (0)
Targeting Isoprenylcysteine Carboxyl Methyltransferase to Overcome Resistance and Improve Responses in Chronic Myeloid Leukemia. (2009) (0)
Monitoring CML after nonmyeloablative transplantations: how negative is negative? (2003) (0)
Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients. (2009) (0)
RESEARCH PAPER Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells (2009) (0)
HOX Genes - Candidate Tumor Suppressor Genes in Adult and Childhood Leukemia. (2007) (0)
Selective Inhibition of Lysophosphatidic Acid Acyltransferase-β by CT32228 Inhibits MAPK and Enhances the Antileukemic Activity of Imatinib in BCR-ABL Expressing Cell Lines Resistant to Imatinib. (2005) (0)
Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL). (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Junia V. Melo?

Junia V. Melo is affiliated with the following schools:

Junia V. Melo's Academic­Influence.com Rankings

Why Is Junia V. Melo Influential?

Junia V. Melo's Published Works

Published Works

What Schools Are Affiliated With Junia V. Melo?

Junia V. Melo's AcademicInfluence.com Rankings